Physician profile
Eric Jay Betts
NPI 1336132679
$8,460.72
in general payments reported to CMS, 2019-2025
50 companies · $1,956 in 2025
The $1,956 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $586 · 2021: $1,046 · 2022: $1,038 · 2023: $1,830 · 2024: $1,478 · 2025: $1,956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,264.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,131.49 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $767.45 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $681.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $662.74 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $549.86 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Lilly USA, LLC | $546.67 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $490.71 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $404.62 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $332.99 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $326.36 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.99 | 2019-2024 | Ofev, Jardiance |
| Lundbeck LLC | $242.48 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $193.60 | 2019-2024 | Steglatro, Belsomra, Gardasil 9 |
| Sumitomo Pharma America, INC. | $183.24 | 2023-2025 | Gemtesa |
| Amgen INC. | $165.41 | 2019-2024 | Otezla, Repatha |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Betts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.